These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15068504)

  • 21. [Sex-specific analysis of bone mass in normal and growth hormone transgenic mice using dual energy x-ray absorptiometry (DXA)].
    Lochmüller EM; Weusten A; Wolf E; Cindik E; Renner-Müller I; Eikmeier T; Eckstein F
    Ann Anat; 1999 Mar; 181(2):191-8. PubMed ID: 10332523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disruption of four-and-a-half LIM 2 decreases bone mineral content and bone mineral density in femur and tibia bones of female mice.
    Govoni KE; Baylink DJ; Chen J; Mohan S
    Calcif Tissue Int; 2006 Aug; 79(2):112-7. PubMed ID: 16927043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular response of bone to growth hormone during skeletal unloading: regional differences.
    Bikle DD; Harris J; Halloran BP; Currier PA; Tanner S; Morey-Holton E
    Endocrinology; 1995 May; 136(5):2099-109. PubMed ID: 7720659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms.
    Mohan S; Richman C; Guo R; Amaar Y; Donahue LR; Wergedal J; Baylink DJ
    Endocrinology; 2003 Mar; 144(3):929-36. PubMed ID: 12586770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pamidronate prevents bone loss and decreased bone strength in adult female and male rats fed an isocaloric low-protein diet.
    Mekraldi S; Toromanoff A; Rizzoli R; Ammann P
    J Bone Miner Res; 2005 Aug; 20(8):1365-71. PubMed ID: 16007334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced bone mineral density in SOCS-2-deficient mice.
    Lorentzon M; Greenhalgh CJ; Mohan S; Alexander WS; Ohlsson C
    Pediatr Res; 2005 Feb; 57(2):223-6. PubMed ID: 15585682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice.
    Windahl SH; Vidal O; Andersson G; Gustafsson JA; Ohlsson C
    J Clin Invest; 1999 Oct; 104(7):895-901. PubMed ID: 10510330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender specific LRP5 influences on trabecular bone structure and strength.
    Dubrow SA; Hruby PM; Akhter MP
    J Musculoskelet Neuronal Interact; 2007; 7(2):166-73. PubMed ID: 17627087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A postweaning reduction in circulating ghrelin temporarily alters growth hormone (GH) responsiveness to GH-releasing hormone in male mice but does not affect somatic growth.
    Ariyasu H; Iwakura H; Yamada G; Kanamoto N; Bando M; Kohno K; Sato T; Kojima M; Nakao K; Kangawa K; Akamizu T
    Endocrinology; 2010 Apr; 151(4):1743-50. PubMed ID: 20185766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat.
    Kapitola J; Zák J; Lacinová Z; Justová V
    Physiol Res; 2000; 49 Suppl 1():S101-6. PubMed ID: 10984078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
    Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
    J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of bone metabolism in immunosuppressant (FK506)-treated rats.
    Kirino S; Fukunaga J; Ikegami S; Tsuboi H; Kimata M; Nakata N; Nakano M; Ueno T; Mizukawa N; Sugahara T
    J Bone Miner Metab; 2004; 22(6):554-60. PubMed ID: 15490265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A time course of bone response to jump exercise in C57BL/6J mice.
    Umemura Y; Baylink DJ; Wergedal JE; Mohan S; Srivastava AK
    J Bone Miner Metab; 2002; 20(4):209-15. PubMed ID: 12115066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects.
    Amato G; Izzo G; La Montagna G; Bellastella A
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):27-32. PubMed ID: 8796135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: evidence from pubertal mouse models.
    Callewaert F; Venken K; Kopchick JJ; Torcasio A; van Lenthe GH; Boonen S; Vanderschueren D
    J Bone Miner Res; 2010 Mar; 25(3):617-26. PubMed ID: 19888832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial.
    Bex M; Abs R; Maiter D; Beckers A; Lamberigts G; Bouillon R
    J Bone Miner Res; 2002 Jun; 17(6):1081-94. PubMed ID: 12054164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone Mass and Strength are Significantly Improved in Mice Overexpressing Human WNT16 in Osteocytes.
    Alam I; Reilly AM; Alkhouli M; Gerard-O'Riley RL; Kasipathi C; Oakes DK; Wright WB; Acton D; McQueen AK; Patel B; Lim KE; Robling AG; Econs MJ
    Calcif Tissue Int; 2017 Apr; 100(4):361-373. PubMed ID: 28013361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of 24 months of growth hormone (GH) treatment on serum carboxylated and undercarboxylated osteocalcin levels in GH-deficient adults.
    Hubina E; Lakatos P; Kovács L; Szabolcs I; Rácz K; Tóth M; Szucs N; Góth MI
    Calcif Tissue Int; 2004 Jan; 74(1):55-9. PubMed ID: 14508626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo.
    Bouxsein ML; Rosen CJ; Turner CH; Ackert CL; Shultz KL; Donahue LR; Churchill G; Adamo ML; Powell DR; Turner RT; Muller R; Beamer WG
    J Bone Miner Res; 2002 Apr; 17(4):570-9. PubMed ID: 11918215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
    Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
    J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.